Skip to main content
. 2021 Nov 23:M21-3480. doi: 10.7326/M21-3480

Table 2.

Grade 1 and 2 Adverse Events Among All Participants in the Placebo and mRNA-1273 Groups (n = 120) Within 7 Days of the Third Dose*

Table 2. Grade 1 and 2 Adverse Events Among All Participants in the Placebo and mRNA-1273 Groups (n = 120) Within 7 Days of the Third Dose*